NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$56.9m

Last Updated

2021/04/16 23:05 UTC

Data Sources

Company Financials +

Executive Summary

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States. More Details


Snowflake Analysis

Adequate balance sheet unattractive dividend payer.

Share Price & News

How has ProPhase Labs's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PRPH is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: PRPH's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

1.7%

PRPH

2.3%

US Pharmaceuticals

1.3%

US Market


1 Year Return

198.3%

PRPH

8.9%

US Pharmaceuticals

53.9%

US Market

Return vs Industry: PRPH exceeded the US Pharmaceuticals industry which returned 8.9% over the past year.

Return vs Market: PRPH exceeded the US Market which returned 53.9% over the past year.


Shareholder returns

PRPHIndustryMarket
7 Day1.7%2.3%1.3%
30 Day-24.3%1.3%3.3%
90 Day-66.4%-0.6%8.9%
1 Year198.3%198.3%13.1%8.9%56.6%53.9%
3 Year198.6%80.8%38.5%26.5%64.4%53.6%
5 Year556.9%297.8%46.8%27.7%120.4%95.7%

Long-Term Price Volatility Vs. Market

How volatile is ProPhase Labs's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ProPhase Labs undervalued compared to its fair value and its price relative to the market?

10.1%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PRPH ($5.37) is trading below our estimate of fair value ($5.98)

Significantly Below Fair Value: PRPH is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: PRPH is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: PRPH is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PRPH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PRPH is overvalued based on its PB Ratio (5.9x) compared to the US Pharmaceuticals industry average (3.8x).


Future Growth

How is ProPhase Labs forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

19.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if PRPH's forecast earnings growth is above the savings rate (2%).

Earnings vs Market: Insufficient data to determine if PRPH's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if PRPH's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if PRPH's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PRPH's Return on Equity is forecast to be high in 3 years time


Past Performance

How has ProPhase Labs performed over the past 5 years?

2.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PRPH is currently unprofitable.

Growing Profit Margin: PRPH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PRPH is unprofitable, but has reduced losses over the past 5 years at a rate of 2.1% per year.

Accelerating Growth: Unable to compare PRPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PRPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.8%).


Return on Equity

High ROE: PRPH has a negative Return on Equity (-22.03%), as it is currently unprofitable.


Financial Health

How is ProPhase Labs's financial position?


Financial Position Analysis

Short Term Liabilities: PRPH's short term assets ($15.9M) exceed its short term liabilities ($6.3M).

Long Term Liabilities: PRPH's short term assets ($15.9M) exceed its long term liabilities ($14.6M).


Debt to Equity History and Analysis

Debt Level: PRPH's debt to equity ratio (94.6%) is considered high.

Reducing Debt: PRPH's debt to equity ratio has increased from 16.7% to 94.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PRPH has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PRPH has sufficient cash runway for 2.3 years if free cash flow continues to grow at historical rates of 24.1% each year.


Dividend

What is ProPhase Labs's current dividend yield, its reliability and sustainability?

4.66%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: PRPH's dividend (4.66%) is higher than the bottom 25% of dividend payers in the US market (1.24%).

High Dividend: PRPH's dividend (4.66%) is in the top 25% of dividend payers in the US market (3.46%)


Stability and Growth of Payments

Stable Dividend: Too early to tell whether PRPH's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if PRPH's dividend payments are increasing as they only just started paying a dividend.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.8yrs

Average board tenure


CEO

Ted Karkus (61 yo)

11.83yrs

Tenure

US$249,000

Compensation

Mr. Ted William Karkus has been the Chief Executive Officer of ProPhase Labs, Inc. since June 2009. Mr. Karkus founded 2001 Forrester Financial LLC and served as its Managing Member. He is a Management Con...


CEO Compensation Analysis

Compensation vs Market: Ted's total compensation ($USD249.00K) is below average for companies of similar size in the US market ($USD543.98K).

Compensation vs Earnings: Ted's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: PRPH's board of directors are considered experienced (8.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 30.8%.


Top Shareholders

Company Information

ProPhase Labs, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ProPhase Labs, Inc.
  • Ticker: PRPH
  • Exchange: NasdaqCM
  • Founded: 1989
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$56.885m
  • Shares outstanding: 15.15m
  • Website: https://www.prophaselabs.com

Number of Employees


Location

  • ProPhase Labs, Inc.
  • 711 Stewart Avenue
  • Suite 200
  • Garden City
  • New York
  • 11530
  • United States

Listings


Biography

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States....


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/16 23:05
End of Day Share Price2021/04/16 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.